Stay updated on Quest Diagnostics Press Releases

Sign up to get notified when there's something new on the Quest Diagnostics Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Quest Diagnostics Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    Added a Europe-based cancer monitoring test announcement; removed an unrelated Quest Diagnostics dividend press release.
    Difference
    14%
    Check dated 2025-10-19T16:08:43.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Significant additions: Quest Diagnostics financial results date, Epic collaboration, and Haystack Oncology/Rutgers/Mass General Brigham collaborations; deletions remove extensive navigation and customer flow text and an error page, reducing clutter but not negating the new strategic announcements.
    Difference
    100%
    Check dated 2025-09-28T02:57:50.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Major expansion and reorganization of patient- and clinician-focused content (appointments, tests, results, insurance, test directory, clinical trials) with updated navigation; removal of a July 2025 quarterly earnings press release.
    Difference
    100%
    Check dated 2025-09-20T22:02:40.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Quest Diagnostics has introduced a new advanced pharmacogenomics offering and reported significant findings regarding fentanyl positivity in drug tests, while also removing information about testing for the Oropouche virus and an FDA-cleared blood test for Alzheimer's disease.
    Difference
    100%
    Check dated 2025-09-06T14:47:01.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The webpage has added significant information regarding a joint venture between Corewell Health and Quest Diagnostics to enhance laboratory services in Michigan, as well as the FDA granting Breakthrough Device Designation for a new circulating tumor DNA test. However, several corporate announcements and reports from Quest Diagnostics have been removed.
    Difference
    100%
    Check dated 2025-08-30T11:33:47.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    Quest Diagnostics has announced its participation in the Baird 2025 Global Healthcare Conference and declared a quarterly cash dividend of $0.80 per share. However, the company has removed information regarding its collaboration with MD Anderson for a multi-cancer blood test.
    Difference
    100%
    Check dated 2025-08-16T04:31:32.000Z thumbnail image

Stay in the know with updates to Quest Diagnostics Press Releases

Enter your email address, and we'll notify you when there's something new on the Quest Diagnostics Press Releases page.